How Supplied


NDC No.
63323-
Product
No.
Description Concentration Strength Vial
Size/
Fill
Closure Pack
Size
Min.
Direct
Order
Qty.
285-65 278565 SD Infusion
Bottle
2 mg/mL 0.20% 100 mL 28 mm 1 12 x 1
285-64 278564 SD Infusion
Bottle
2 mg/mL 0.20% 200 mL 28 mm 1 12 x 1
285-10 278510 Polyamp
DuoFit®
Sterile Pak
2 mg/mL 0.20% 10 mL N/A 5 24 x 5
285-20 278520 Polyamp
DuoFit®
Sterile Pak
2 mg/mL 0.20% 20 mL N/A 5 20 x 5
286-20 278620 Polyamp
DuoFit®
Sterile Pak
5 mg/mL 0.50% 20 mL N/A 5 20 x 5
286-30 278630 SD Vial 5 mg/mL 0.50% 30 mL 20 mm 1 50 x 1
286-31 278631 Sterile-Pak
SD Vial
5 mg/mL 0.50% 30 mL 20 mm 5 10 x 5
287-20 278720 Polyamp
DuoFit®
Sterile Pak
7.5 mg/mL 0.75% 20 mL N/A 5 20 x 5
288-10 278810 Polyamp
DuoFit®
Sterile Pak
10 mg/mL 1% 10 mL N/A 5 24 x 5
288-20 278820 Polyamp
DuoFit®
Sterile Pak
10 mg/mL 1% 20 mL N/A 5 20 x 5

BAR CODED • LATEX FREE • PRESERVATIVE FREE




Important Safety Information

Using NAROPIN beyond recommended doses to increase motor block or duration of sensory block may negate its favorable cardiovascular advantages, in the event that an inadvertent intravascular injection occurs.
Like all amide-type local anesthetics, NAROPIN may be associated with adverse reactions. In clinical trials, side effects were mild and transient and may reflect the procedures, patient health status, and/or other medications used. Adverse events reported at a rate of ≥5%: hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain.

New Safety Information

There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. NAROPIN is not approved for this use.

Please see Full Prescribing Information at www.naropin-us.com.



NAROPIN® and logo are registered trademarks of APP Pharmaceuticals, LLC.
®
and APP® are registered trademarks of APP Pharmaceuticals, LLC.
©2010, APP Pharmaceuticals, LLC. All Rights Reserved.